Volume 29, Issue 10 (1-2022)                   JSSU 2022, 29(10): 4198-4208 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rajabi M, Miresmaeili S M, Montazri F, Nasresfahani M, Zieai S J, Kalantar S M. Evaluating Mirna-222 Expression Level and Its Association with AMH for Early Diagnosis of Pcos-Like Symptoms in Epileptic Patients Plasma Treated with Sodium Valproate: A Case – Control Study. JSSU 2022; 29 (10) :4198-4208
URL: http://jssu.ssu.ac.ir/article-1-4946-en.html
Abstract:   (1022 Views)
Introduction: Epileptic neurological disorder, which is controlled with medications such as sodium valproate (one of the treatment priorities for the patients with epilepsy). Polycystic ovary syndrome (PCOS) is one of complication of sodium valproate. Ovulation in PCOs Patients is disrupted, resulting in serious complications, including endometrial hyperplasia with typical and atypical forms, increased the risk of endometrial endometrial cancer, diabetes mellitus, and decreased fertility rates. This study, in accordance with bioinformatics studies and other studies based on the association of miRNA-222 with genes involved in PCOs and hyperandrogenism, was designed to evaluate the association of PCOs in the patients treated with sodium valproate by simultaneously comparing the AMH factor and miRNA-222 marker at specific time periods.
Methods: In this case-control study, 33 women with epilepsy before and after use the drug were selected based on inclusion and exclusion criteria. After blood sampling, their plasma was isolated. According to the instructions of the Total RNA extracted kit , cDNA synthesized and miRNA-222 expression was evaluated by RT-qPCR technique and statistical analysis was performed by SPSS 23 software, T-test and ANOVA tests.
Results: The results of statistical tests such as T-test and ANOVA test (done with SPSS software) which showed a significant difference (p<0/01) between the mean expression of mir-222 and AMH in the patients before treatment compared to 3 month after treatment. The results of Pearson correlation test showed that the increase in AMH is directly related to the decrease in miRNA-222 expression (p<0/01).
Conclusion: According to the results of the present study, in order to better control the possible side effects of the drug and possibly timely drug change and early diagnosis of PCOs (PCOs‌-like symptoms), evaluation of miRNA-222 expression changes can be used at the same time with AMH assay.
Full-Text [PDF 1181 kb]   (418 Downloads)    
Type of Study: clinical trial | Subject: Genetics
Received: 2019/07/29 | Accepted: 2021/12/31 | Published: 2021/12/31

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | SSU_Journals

Designed & Developed by : Yektaweb